Clinical outcomes from non-muscle-invasive bladder cancer (NMIBC) are partly determined by the quality of initial interventions. To improve and standardise treatment for cancer, Scotland implemented a national Quality Performance Indicator (QPI) programme for bladder cancer (BC).
As Bladder Cancer (BC) is very heterogeneous and complicated in the genetic level, exploring genes to serve as biomarkers and therapeutic targets is practical. We searched Gene Expression Omnibus (GEO) and downloaded the eligible microarray datasets.
To identify patients who can safely evade the magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion. Overall, 755 men with PI-RADS 3-5 lesions who underwent MRIFTB were retrospectively analyzed.
In the past decade rigorous debate has taken place about population-based screening for prostate cancer. Although screening by serum PSA levels can reduce prostate cancer-specific mortality, it is unclear whether the benefits outweigh the risks of false-positive results and overdiagnosis of insignificant prostate cancer, and it is not recommended for population-based screening.
Alicia Morgans: Hi, this is Alicia Morgans, GU medical oncologist and associate professor of medicine at Northwestern University. And I am so excited to have here with me today, a good friend and colleague, Dr. Petros Grivas, who is an associate professor of medicine and a GU medical oncologist at the University of Washington in Seattle. […]
Dear Colleagues, Welcome to the second issue of Everyday Urology – Oncology Insights of 2020, published by Digital Science Press. Throughout the year, UroToday.com has provided information and expert perspectives on the evolving state of urology and GU oncology, as well as the impact COVID-19 has had on the healthcare environment, featuring video discussions amongst […]
Introduction Prostate cancer, while commonly diagnosed in early forms, remains the second leading cause of cancer mortality in the United States and Europe.1 For patients who die of prostate cancer, some will be initially diagnosed and treated for metastatic castration-sensitive disease (mCSPC) while others will progress through non-metastatic castration-resistant disease (nmCPRC) following initial local therapy […]
Patients with non-metastatic castration-resistant prostate cancer (nmCRPC, formerly known as M0 CRPC) have rising prostate-specific antigen (PSA) levels despite castrate levels of testosterone with approved androgen deprivation therapy (ADT) and no detectable metastases on conventional imaging with computed tomography (CT) and bone scans.1
On March 26, 2020, the first 4 SARS-CoV-2 patients were reported in Switzerland. The number of cases increased rapidly and some Swiss cantons were severely affected by the pandemic.1 At the time a humanitarian crisis was unfolding in Bergamo1 and increased awareness on how the pandemic could affect cancer care.
Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.
